(Q33396384)

26 July 2017

title

Bevacizumab and daily temozolomide for recurrent glioblastoma (English)

1 reference

26 July 2017

1 reference

0 references

1 reference

April Coan

3

0 references

Henry Seth Friedman

series ordinal

8

object named as

Henry S Friedman

1 reference

26 July 2017

1

Annick Desjardins

1 reference

26 July 2017

2

David A Reardon

1 reference

26 July 2017

9

James J Vredenburgh

1 reference

26 July 2017

7

Katherine B Peters

1 reference

26 July 2017

5

James E Herndon

1 reference

26 July 2017

4

Jennifer Marcello

1 reference

26 July 2017

6

Leighann Bailey

1 reference

26 July 2017

language of work or name

English

0 references

publication date

26 July 2011

1 reference

26 July 2017

1 reference

26 July 2017

volume

118

1 reference

26 July 2017

issue

5

1 reference

26 July 2017

page(s)

1302-1312

1 reference

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

Irinotecan therapy in adults with recurrent or progressive malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

The anti-angiogenic basis of metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

Angiogenesis in malignant primary and metastatic brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

Vascular endothelial growth factor: basic science and clinical progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

Radiographic patterns of relapse in glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26381

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.26381

1 reference

26 July 2017

1 reference